To read more on this topic click here.
Inhalable drug given green light
Author: Simge Eva DoganPublished: 9 January 2019
Prep: Cook: Serves:
The US Food and Drug Administration (FDA) has approved INBRIJA – an inhalable drug created by US biotech company Acorda Therapeutics – for intermittent treatment.
INBRIJA is designed to treat Parkinson’s symptoms that occur between oral doses of medication, which are known as ‘off’ episodes. The drug has been approved by the FDA and – after a clinical study involving 900 people with Parkinson’s – is expected to be available in 2019.
Todd Sherer, CEO of The Michael J Fox Foundation, who funded early trials of the powder, said: “Despite being on treatment, patients may experience OFF periods as Parkinson’s progresses, which can be disruptive.
“We knew we had to help address this unmet need, and this approval is a significant step forward for the community as it provides a new option to manage these gaps in symptom control.”
For more information on Parkinson’s medication please visit Parkinson’s Europe website.
Share this story
Pedalling for Parkinson’s
We talk to the founder of The Bike Box Project in New Bern, North CarolinaREAD MORE
From small steps to big leaps – 200 years of Parkinson’s disease research and therapy advancements
Advice from experts working to enhance Parkinson’s therapy optionsREAD MORE
On World Parkinson’s Day 2018 we #UniteForParkinsons
The world came together to join the #UniteForParkinsons campaignREAD MORE